Gains

Cancer

Major

Strong

Bank

<h3 id="key-highlights">Key Highlights</h3>
<ul>
 <li>The pharmaceutical giant reached a fresh 52-week peak of $29.09 during Tuesday’s session, closing at $28.75</li>
 <li>Second quarter 2026 results surpassed Wall Street projections: earnings per share of $0.77 versus consensus of $0.68, revenues of $15.03B against estimates of $14.42B</li>
 <li>Management increased full-year 2026 revenue projections after the quarterly performance</li>
 <li>Settlement reached on more than 6,000 federal lawsuits related to Depo-Provera, eliminating significant legal uncertainty</li>
 <li>Wall Street analysts maintain a “Hold” consensus with a mean target price of $28.28</li>
</ul>
Shares of Pfizer reached a new 52-week peak of $29.09 during Tuesday’s trading session, ultimately settling at $28.75. This performance represents approximately 20% gains year-to-date, marking a significant recovery for the pharmaceutical company that has been working through the aftermath of declining COVID-related revenues over the past two years.
<a href="https://knockoutstocks.com/stock/PFE" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/PFE/embed" alt="PFE Stock Card"> Pfizer Inc., PFE </a>
Trading volume reached more than 8.3 million shares, exceeding normal activity levels and indicating heightened investor attention.
The upward momentum follows a robust second quarter 2026 financial report. The company delivered adjusted earnings per share of $0.77, exceeding analyst consensus estimates of $0.68 by nine cents. Total revenue reached $15.03 billion, surpassing the anticipated $14.42 billion.
Compared to the corresponding period in the previous year, revenue increased by 2.6%. While modest, this positive growth trajectory has captured market attention.
In response to the strong quarterly performance, <a href="https://coincentral.com/pfizer-pfe-stock-wall-street-says-buy-but-the-valuation-debate-is-real/" rel="noopener noreferrer nofollow">Pfizer</a> elevated its full-year 2026 EPS outlook to a range between $2.80 and $3.00. Wall Street analysts are currently projecting the company will achieve $2.98 for the complete fiscal year.
Erste Group Bank also increased its fiscal 2026 earnings per share projection for Pfizer following the quarterly results, contributing to the favorable sentiment surrounding the report.
<h3 id="legal-uncertainty-eliminated-with-depo-provera-agreement">Legal Uncertainty Eliminated with Depo-Provera Agreement</h3>
A significant development this week involves the conclusion of Depo-Provera-related litigation. The pharmaceutical company achieved a confidential settlement agreement encompassing more than 6,000 federal lawsuits alleging connections between the contraceptive and intracranial meningioma.
While specific financial details remain undisclosed and the company acknowledged no wrongdoing, removing this legal uncertainty from the equation carries meaningful weight. The investment community had been monitoring this litigation closely, and its conclusion eliminates a substantial overhang.
<h3 id="cancer-treatment-portfolio-gains-traction">Cancer Treatment Portfolio Gains Traction</h3>
<a href="https://coincentral.com/pfizer-inc-pfe-stock-surge-as-ema-validates-lyme-vaccine-application-after-strong-phase-3-results/" rel="noopener noreferrer nofollow">Pfizer’s</a> cancer treatment division continues attracting analyst focus. Padcev currently leads growth within this segment, while the company maintains additional development programs including PF-08634404 that may bolster future revenue streams.
Expanded label indications in oncology are being monitored as potential counterbalances to challenges in other business areas as legacy products encounter generic competition.
Regarding shareholder returns, the company distributed $0.43 per share quarterly on September 1st to investors recorded as of July 24th. This translates to an annualized dividend of $1.72 and yields approximately 6%.
This attractive yield has positioned PFE as a popular topic among investors seeking income-producing holdings while technology and artificial intelligence stocks maintain elevated valuations.
Wall Street opinion remains divided. Royal Bank of Canada elevated the stock from underperform to sector perform in June, whereas HSBC downgraded it from buy to hold in July while reducing its price target from $32 to $28. Cantor Fitzgerald maintains a neutral stance with a $27 objective, and Wolfe Research continues an underperform rating with a $26 target.
The aggregate consensus stands at “Hold” with a mean price objective of $28.28, marginally below the stock’s current trading level.
Institutional ownership comprises 68.36% of outstanding shares. Multiple smaller investment funds established new positions during the first and second quarters of 2026.
The stock’s 50-day moving average currently sits at $25.62 while the 200-day moving average rests at $26.30, both positioned considerably beneath the present price level.
The post <a href="https://blockonomi.com/pfizer-pfe-stock-surges-to-52-week-peak-following-strong-q2-results-and-major-legal-settlement/" rel="noopener noreferrer nofollow">Pfizer (PFE) Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Pfizer (PFE) Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement

Table of Contents

Blockonomi

Other articles published on Sep 1, 2026

Join our free newsletter for daily crypto updates!